SEC Tracker
Get the app

Cartesian Therapeutics RNAC

Cartesian Therapeutics (RNAC) announced the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change comes as the company navigates a critical phase in the development of its lead drug candidate, which is currently in late-stage clinical trials. Investors should closely monitor the company's ability to ensure a smooth transition and maintain momentum in its pipeline.

Form
8-K
Filed
Importance
Major

Open in the appGet the appView on EDGAR

Get an email when Cartesian Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  2. Atossa Therapeutics ATOS public float $107M, Jun 30, 2025
  3. Enanta Pharmaceuticals ENTA public float $111M, Mar 31, 2025, over 18 months old
  4. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  5. Fennec Pharmaceuticals FENC public float $106M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.